肝动脉插管化疗栓塞加无水酒精注射治疗原发性肝癌

目前大多数学者认为原发性肝癌需要综合治疗．但选用哪些方法组合为优，目前尚无定论。1992年7月至1997年1局，我们选用肝动脉插管化疗栓塞（TAE）加无水酒精注射（PEIT）联合治疗原发性肝癌43例．获得满意疗效，现报告如下：资料与方法一般资料：本组43例，年龄18～69岁，平均     

射频消融治疗肝细胞肝癌的长期疗效

目的：研究影响231例肝细胞癌（HCC）射频消融（RFA）疗效的预后因素，并评价其疗效。方法：231例HCC患在1999年到2005年间接受RFA治疗，其中160例为原发HCC，71例为复发HCC。通过单因素和多因素模型分析了25个潜在因素，以确定影响生存率的预后因素。结果：1，3，5年的生存率分别为84．7％，55．8％，40．7％。     

经皮集束电极射频消融治疗小肝癌

目的 探讨经皮集束电极射频消融(radiofrequency ablation,RFA)对小肝癌(直径≤3cm)的治疗效果。方法利用RF-2000TM肿瘤射频治疗系统,在B超引导下对21例小肝癌患者24个肿块进行经皮肝穿刺射频热凝治疗,并用B超及CT检查以了解RFA治疗效果,随访观察其复发和生存情况。结果 RFA治疗后100％(20/20)的肿块血供消失(另4个治疗前即无血供),且2,4个肿块呈完全凝固性坏死(100％)。随访6月-3年,21侧中存活19例,半年生存率100％。存活的19例中,已有5例生存半年,4例生存1年,6例生存2年,4例生存3年。结论 集束电极RFA治疗小肝癌创伤小,安全,疗效可靠。     

B超引导下经皮肿瘤内注射无水酒精治疗原发性肝癌

原发性肝癌(下称肝癌)除手术切除和介入放射治疗外,近年来,国内外已开展了B超引导下经皮肿瘤内注射无水酒精(PEIT)和经皮门静脉内注入无水酒精(PPEE)并行肝动脉栓塞(TAE)的治疗方法。这被日本学者认为是继肝癌第一代全身化疗和第二代手术切除后的第三代治疗方法。在临床实践中也已取得令人满意的疗效。为了进一步开展PEIT和PPEE,就其目前基础研究、临床应用与疗效等作一简要综述。     

无水酒精-碘化油栓塞治疗原发性肝癌

目的评价无水酒精-碘化油经导管动脉栓塞(TAE)对原发性肝癌(HCC)的疗效.材料与方法17例患者进行了20次TAE治疗.无水酒精与碘化油体积比为11～13,充分超选择栓塞,观察治疗前后AFP、CT、DSA的变化.结果20例次均成功地进行了肝脏亚段、亚-亚段栓塞,栓塞后DSA表现为肿瘤血管闭塞、肿瘤染色消失,肿瘤血管再通及侧枝循环形成均明显减少;CT显示肿瘤明显缩小、肿瘤内碘化油聚集明显且排空延迟.无明显副作用发生.结论无水酒精-碘化油TAE治疗HCC具有操作简便、副作用小、肿瘤血管再通及侧枝循环形成少的特点,可明显增强栓塞效果,同时减少TAE次数.     

射频消融治疗肝细胞肝癌

肝细胞肝癌(hepatoeellular carcinoma,HCC)是一种常见的恶性肿瘤,由于HCC恶性程度高、发展迅速,加上患者多有肝硬化基础、肝功能储备差,HCC有多发和肝内播散倾向,病灶邻近大血管、胆管等因素,仅5％～15％的患者可以接受根治性切除术。因此动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)、热疗、冷冻治疗、经皮无水酒精注射(percutaneous ethanol iniection,PEI)等非手术疗法在HCC治疗中占据重要地位。作为热疗的一种,射频消融(radiofrequency abhtion,RFA)近年来发展迅速,并在临床上取得较好疗效,现综述如下。     

肝动脉栓塞化疗联合射频消融与联合微波消融治疗原发性肝癌的疗效和安全性比较

目的 对比肝动脉栓塞化疗(TACE)联合射频消融(RFA)或联合微波消融(MWA)的近期局部疗效、安全性及生存率.方法 回顾性分析采用TACE联合RFA治疗或联合MWA治疗的原发性肝癌患者,比较两组术后AFP、肝功能、不良反应、并发症、术后3个月的影像学表现以及1年生存率情况.结果 射频联合组术后3个月边缘复发率9.8％,微波联合组23.7％,差异无统计学意义(P＞0.05);射频联合组术后AFP平均下降为(412.47±373.81) ng/ml,微波联合组平均下降为(278.72±269.20) ng/ml,差异无统计学意义(P＞0.05);术后射频联合组ALT平均升高至(81.22±49.50) U/L、AST平均升高至(93.71±50.94) U/L,微波联合组ALT平均升高至(139.53±97.77) U/L,AST平均升高至(181.43±140.16) U/L;两组ALT及AST对比有统计学意义(P＜0.001);两组术后不良反应无明显差异,射频联合组并发症1例,微波联合组并发症2例,差异无统计学意义(P＞0.05),两组术后均未出现与治疗相关的死亡病例,1年生存率无差异(P＞0.05).结论 TACE联合RFA或联合MWA的近期局部疗效、并发症及1年生存率无显著差异,但射频联合组术后比微波联合组术后肝功能损伤轻微.     

经皮射频消融术与根治性切除术在小肝癌治疗中的疗效研究

目的探讨经皮射频消融术(RFA)治疗小肝癌的效果。方法将经影像学、病理学检查证实的小肝癌患者116例分为两组,分别行RFA和手术切除治疗,比较两组术后并发症的发生、术后1年两组肿瘤复发率及1、2、3年生存率。结果 RFA治疗组并发症发生率明显低于手术组,两组术后1年肿瘤复发率及1、2、3年生存率无统计学差异。结论对于小肝癌,肝功能不能耐受手术治疗或肿瘤实质位于靠近主要血管、胆管,切除困难的患者,RFA治疗具有与手术相同的效果,且并发症少。     

经皮射频消融联合乙醇消融治疗肾上腺转移癌

目的总结CT导向下冷循环射频消融(RFA)联合乙醇消融(PEI)治疗肾上腺转移癌的效果和经验。方法采用CT导向下冷循环RFA联合PEI治疗18例肾上腺转移癌患者共21个病灶,术后复查增强CT或MR,观察病灶坏死情况。结果18个病灶完全坏死,3个病灶大部分坏死,病灶完全坏死率86%,无严重并发症。结论CT导向下冷循环RFA联合PEI治疗肾上腺转移癌安全、有效。     

重复射频消融治疗原发性肝癌的临床疗效观察

目的评价经皮肝穿刺重复射频消融治疗原发性肝癌的临床疗效。方法将88例原发性肝癌患者按单次射频消融及重复射频消融的方法分为2组,观察每组肿瘤完全消融率、肿瘤复发率及不良反应的发生情况。结果2组均未发生出血、胆漏等严重的不良反应。单次射频消融组肿瘤的完全消融率为62．5％,重复射频消融组为87．5％,2组间比较差异有统计学意义（P〈O．05）;单次射频消融组肿瘤的复发率为20．0％,重复射频消融组为4．2％,2组间比较差异有统计学意义（P〈O．05）。结论重复射频消融可有效提高原发性肝癌的临床治疗效果。     

腹腔镜射频消融治疗原发性肝癌的研究

目的：评价腹腔镜射频消融（RFA）治疗原发性肝癌的可行性、安全性及疗效。方法：51例原发性肝癌在全麻下行腹腔镜RFA治疗,共72个瘤体,平均最大肿瘤直径（3．4±1．0）cm。合并肝硬化49例、慢性结石性胆囊炎5例,糖尿病4例,凝血功能障碍10例。结果：51例均顺利完成腹腔镜RFA治疗,12例行腹腔镜胆囊切除术。未出现严重并发症。肿瘤完全坏死率为95．8％。随访12～58个月（平均35个月）,6例发现肝内新病灶,11例射频治疗部位复发,再次采用经皮RFA治疗9例,12例死于肿瘤复发或肝功能衰竭。结论：腹腔镜RFA治疗原发性肝癌安全可行,治疗效果可靠,但应选择瘤体位于肝脏表面或临近胆囊而且不宜手术切除的病例进行治疗。     

Single-session combined radiofrequency ablation and transarterial chemoembolization in the treatment of hepatocellular carcinoma

Aim of the study

To evaluate the efficacy of the combined use of both transarterial chemoembolization (TACE) and percutaneous radiofrequency ablation (RFA) in a single session for the treatment of large (≥3?cm in diameter) hepatocellular carcinoma.

超声引导下射频消融治疗肝癌安全性与疗效分析

目的探讨超声引导下射频消融方法治疗肝癌的安全性与临床效果。方法选取我院2010年7月-2013年7月收治的35例肝癌患者,共61个病灶实施超声引导下经皮射频消融治疗,观察患者并发症情况及肿瘤消融情况,对比分析治疗前后的甲胎蛋白值、肿瘤大小及瘤体内的血供情况。结果所有病灶均消融成功,无严重并发症发生。经过4-15个月随访,复发13例,均给予再次射频消融。结论经皮射频消融治疗肝癌是一种安全、有效的热消融治疗技术,值得临床推广应用。     

Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation

AIM: To investigate the therapeutic efficacy of thermal ablation for treatment of hepatocellular carcinoma (HCC) using microwave and radiofrequency (RF) energy application. MATERIALS AND METHODS: A total of 190 nodules in 97 patients (84 male, 13 female; mean age 53.4 years, range 24-74 years) with HCC were treated with microwave or RF ablation in the last 4 years. The applicators were introduced into the tumours under conscious analgesic sedation by intravenous administration of fentanyl citrate and droperidol and local anaesthesia in both thermal ablation procedures. The patients were then followed up with contrast-enhanced computed tomography (CT) to evaluate treatment response. Survival was analysed using the Kaplan-Meier method. RESULTS: Complete ablation was obtained in 92.6% (176/190) nodules. The complete ablation rates were 94.6% (106/112) in microwave ablation and 89.7% (70/78) in RF ablation. The complete ablation rates in tumours/=4.0 cm were 93.1, 93.8 and 86.4%, respectively. Local recurrence was found in 9.5% nodules and the rates in tumours/=4.0 cm in diameter were 3.4, 9.9 and 31.8%, respectively. In the follow-up period, 7.1% nodules ablated by microwave and 12.8% by RF presented local recurrence. The 1, 2 and 3-year distant recurrence-free survivals were 47.2, 34.9 and 31.0%, respectively. Estimated mean survival was 32 months, and 1, 2 and 3-year cumulative survivals were 75.6, 58.5, and 50.0%, respectively. One and 2 years survivals of Child-Pugh class A, B and C patients were 83.8 and 70.4%, 78.2 and 53.2%, 36.3 and 27.3%, respectively. CONCLUSION: Thermal ablation therapy by means of microwave and RF energy application is an effective and safe therapeutic technique for hepatocellular carcinoma. Large tumours can be completely ablated, but have a significantly higher risk of local recurrence at follow-up.     

The efficacy of intraperitoneal saline infusion for percutaneous radiofrequency ablation for hepatocellular carcinoma

Objective

To evaluated the efficacy and safety of radiofrequency ablation (RFA) with intraperitoneal saline infusion.

Background

Ultrasound-guided RFA is not always feasible due to the tumor location, possible adjacent tissue damage or poor sonographic identification.

Patients and methods

Ultrasound-guided RFA with intraperitoneal saline infusion was performed in 116 patients between June 2001 and March 2008.

Results

The overall technical feasibility of the intraperitoneal saline infusions was 90.5% (105 patients). The purposes of the intraperitoneal saline infusion were achieved in 100 patients (86.2%) by visualizing the tumor located in hepatic dome (47 patients), prevent adjacent organ damage (42 patients) and withdrawing overlying omentum (10 patients). Complete ablation of tumor was accomplished in 102 patients (87.9%). Complications associated with the treatment occurred in seven patients (6.0%). There was no case of adverse event directly related to intraperitoneal saline infusion.

Conclusions

Intraperitoneal saline infusion is an effective and safe procedure that can be used to overcome the current limitations of ultrasound-guided RFA.     

Expandable radiofrequency electrodes for ablation of centrally placed hepatocellular carcinoma

Objective

To regulate the safety, efficacy, complications, and prognostic factors for survival related to the utilize of expandable radiofrequency (RF) electrodes in the treatment of centrally placed hepatocellular carcinoma (HCC).

Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results

The aim of this study was to evaluate the effectiveness and the safety of percutaneous radiofrequency (RF) thermal ablation of hepatocellular carcinoma (HCC) in 88 patients with a long follow-up, and to compare conventional electrodes and expandable electrodes. Eighty-eight patients with 101 hepatocellular carcinoma nodules (≤ 3.5 cm in diameter) underwent RF thermal ablation by means of either conventional electrodes or an expandable electrode. Therapeutic efficacy was evaluated with dynamic contrast CT, serum α-feto protein level, US examination at the end of the treatment, and during follow-up. Complete necrosis was obtained in all tumor nodules in a mean number of 3.3 sessions (tumor treated by conventional electrodes) or 1.5 sessions (tumor treated by expandable electrode). The mean follow-up was 34 months; overall survival rate was 33 % at 5 years. Disease-free survival at 5 years was 3 %; local recurrence rate was 29 % in patients treated with conventional electrodes; 14 % in patients treated with the expandable electrode. Two major complications and 14 minor complications were observed. Radiofrequency thermal ablation in small HCC is very effective with a low percentage of major complications. The use of an expandable electrode substantially reduced the number of treatment sessions but did not modify the overall survival rate and the disease-free survival rate. Received: 7 January 2000 Revised: 19 July 2000 Accepted: 11 August 2000     

不同MR成像方式对肝细胞癌射频消融术后的评估

以射频消融为主的肝细胞癌消融治疗已经广泛应用于临床,但治疗后肿瘤残存和复发是影响疗效的主要问题,所以消融后的评估显得尤为重要.MRI具有多参数、多序列、任意平面成像及多种功能成像方式,使其对肿瘤消融术后的评估更具优势.因此,本文就MRI常规平扫、MRI增强、DWI、DKI、PWI及MRS在肝细胞癌射频消融术后评估中的应...